FDA Approves Roche Lymphoma Drug, Bringing Competition to New AbbVie Med
The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.
Source: medcitynews.com